AstraZeneca’s sipavibart meets endpoints in preventing COVID-19

Positive high-level results have been presented from the SUPERNOVA Phase III COVID-19 pre-exposure prophylaxis (prevention) trial of AstraZeneca’s (LSE: AZN) sipavibart.

The investigational long-acting antibody showed a statistically-significant reduction in the incidence of symptomatic COVID 19 compared to control (tixagevimab/cilgavimab or placebo) in an immunocompromized patient population.

"We will now work with regulatory authorities globally to bring sipavibart to these vulnerable patients"The trial met both dual primary endpoints, the first being the relative risk reduction of symptomatic COVID-19 caused by any SARS-CoV-2 variant, and the second being the relative risk reduction of infections caused by SARS-CoV-2 variants not containing the F456L mutation.